Revolutionizing the future of targeted immune therapeutics
Currently, Q32 Bio has two clinical stage, investigational products being evaluated in clinical trials:
Innate System Modulator
ADX-097 is a tissue-targeted complement inhibitor, which is currently being evaluated in a Phase 1, first-in-human study. The objectives of the study are safety and proof of mechanism. The study is due to be completed in the first half of 2023.
Adaptive System Modulator
ADX-914 is an IL-7 Receptor α-targeted inhibitor, being evaluated in a Phase 2 study of patients with atopic dermatitis.